Creating a highly sensitive test for detecting leftover leukemia cells in patients with Acute Myeloid Leukemia.
Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing
['FUNDING_SBIR_2'] · TWINSTRAND BIOSCIENCES, INC. · NIH-10907583
This study is testing a new blood test that uses advanced technology to better find tiny amounts of leftover leukemia cells in patients with Acute Myeloid Leukemia, helping doctors create more personalized treatment plans and reduce the chance of relapse.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TWINSTRAND BIOSCIENCES, INC. (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10907583 on ClinicalTrials.gov |
What this research studies
This research focuses on improving the detection of minimal residual disease (MRD) in patients with Acute Myeloid Leukemia (AML) using a cutting-edge technology called Duplex Sequencing. Current methods for assessing remission may miss residual leukemia cells, which can lead to relapse. By utilizing Duplex Sequencing, the study aims to enhance the sensitivity of detecting these low-frequency mutations associated with residual leukemia, potentially allowing for more tailored and effective treatment strategies. Patients who participate may undergo blood tests that utilize this advanced sequencing technology to monitor their disease status more accurately.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Acute Myeloid Leukemia who have undergone treatment and are in a state of complete remission.
Not a fit: Patients with other types of leukemia or those who have not been diagnosed with Acute Myeloid Leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more precise monitoring of leukemia patients, potentially reducing relapse rates and improving survival outcomes.
How similar studies have performed: Previous studies have shown promise in using advanced sequencing technologies for similar applications, indicating a potential for success in this novel approach.
Where this research is happening
SEATTLE, UNITED STATES
- TWINSTRAND BIOSCIENCES, INC. — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BICKEL, KELLIE — TWINSTRAND BIOSCIENCES, INC.
- Study coordinator: BICKEL, KELLIE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.